User talk:Amonaroll/sandbox

I am using this as an example--RJBazell (talk) 17:50, 23 October 2018 (UTC)

Helen's Peer Review
The lead of your article is very well done. It gives a good overview in clear enough language that prior knowledge is not necessary to understand your points. You might need citations for some of the statements in this paragraph, however. The organization works with the topic. The reader receives a basic understanding, the problem, and then actions against/in support of these issues. However, I might add a bit more about the the cost of production of drugs. You initially say that the cost is very high, but there is no greater explanation. Your citations seem relevant and reliable. Overall, your work is very informative and easy to understand.

Thank you, I have added more detailed information about costs of HIV drugs. Amonaroll (talk) 02:15, 17 November 2018 (UTC)

Nithya's Peer Review
This is a very informative article highlights issues that are center stage in global war against HIV.

I would like some clarification and elaboration on a few points.

However, because there is a smaller market for such drug treatments, patients must often rely on significantly more expensive originator drugs to receive sufficient treatment. Can you clarify or define what is mean by expensive originator drugs?

In general, low-income countries have the lowest cost of antiretroviral therapy, which is estimated to be $350 per patient per year (pppy), and middle- and high-income tend to have the highest cost of ARV therapy, which is estimated to range from $10,000 to $15,000 pppy.

Please clarify if the middle and high-income countries are using generic ARV therapy and the price is still high or they are using non generic ARV therapy whereas the low income countries are using generic ARV therapy. If so, is generic ARV therapy only available in low income countries? The first-line treatment is generally given to patients as an initial antiretroviral therapy and is the cheapest of the stages of treatments. Can you clarify if the first- line treatment is standardized throughout the world as the only first line therapy or does cost decide first-line therapy by countries?

Despite the high price jump from first-line to second-line treatment, second-line treatment costs have shown a pattern of decline for both originator and generic drugs.

Please explain the reason for decline in second-line treatment cost in both originator and generic group. Why are the second line treatment drugs declining in price from 2014 to 2016?

The article could be enhanced by information about Canada and any role that online pharmacies may play in antiretroviral therapy. Information on developing countries like India where there are government regulations on prices of drugs and availability of generic equivalents would also add to the information provided in this article.

--Nneka's Peer Review-- The article is really well done and clear in its definitions and explanations. The organization and separation of then different sub-topics flow really well. I like how things were separated by country as well. If you wanted to elaborate upon anything, maybe it could include actions to lower drug prices, if however short that section may be. Also, maybe a bit more about the section regarding the consequences of high drug costs. The Brazil section at the end could fit under consequences of high drug cost instead of having its own section. Riley S. Williams (talk) 21:07, 30 October 2018 (UTC)

Thank you for the suggestions, the difference between originator and generic drugs and low, middle, and high income countries has been clarified. Amonaroll (talk) 02:15, 17 November 2018 (UTC)